Clinical Technologies Associates Inc. on Monday said Schering-Plough Corp. will fund a collaboration to see if it will be feasibleto deliver one of Schering's peptides orally using ClinicalTechnologies' microspheres.
The Elmsford, N.Y., company's patented amino acid-basedmicrospheres protect proteins from digestion in the gut,allowing them to enter the bloodstream. The company also hasproduct development agreements for the drug delivery systemwith The Upjohn Co., Sandoz Pharmaceutical Corp. and GeneticsInstitute Inc. (NASDAQ:GENI).
Terms of the Schering agreement and which product will betested were not revealed.
Clinical Technology stock (NASDAQ:CTAI) closed at $23.50,down 13 cents.
REPLIGEN COMPLETES AMIRA ACQUISITION
Repligen Corp. said Monday that it has completed its previouslyannounced acquisition of privately held Amira Inc.
Repligen will issue about 310,000 shares of common stock(NASDAQ:RGEN) to Amira, which will operate as a whollyowned subsidiary of the Cambridge, Mass., company. AtMonday's closing price of $14.63, up 13 cents, the deal is worthabout $4.5 million. Additional shares will be issued if Amira ofWorcester, Mass., meets clinical milestones.
Both companies are focused on virology, cancer andinflammation, with Repligen employing a biological approachand Amira pursuing chemical research.
(c) 1997 American Health Consultants. All rights reserved.